Abstract | Context: Case: Molecular Evaluation: Both prospective clinical sequencing with Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets and retrospective whole-exome sequencing were performed to characterize the molecular alterations in the chemotherapy-naive pituitary adenoma and the temozolomide-resistant liver metastasis. The liver metastasis harbored a somatic mutational burden consistent with alkylator-induced hypermutation that was absent from the treatment-naive tumor. Resistance to temozolomide treatment, acquisition of new oncogenic drivers, and subsequent sensitivity to immunotherapy may be attributed to hypermutation. Conclusion:
|
Authors | Andrew L Lin, Philip Jonsson, Viviane Tabar, T Jonathan Yang, John Cuaron, Katherine Beal, Marc Cohen, Michael Postow, Marc Rosenblum, Jinru Shia, Lisa M DeAngelis, Barry S Taylor, Robert J Young, Eliza B Geer |
Journal | The Journal of clinical endocrinology and metabolism
(J Clin Endocrinol Metab)
Vol. 103
Issue 10
Pg. 3925-3930
(10 01 2018)
ISSN: 1945-7197 [Electronic] United States |
PMID | 30085142
(Publication Type: Case Reports, Journal Article, Research Support, N.I.H., Extramural)
|
Chemical References |
- Ipilimumab
- Nivolumab
- Adrenocorticotropic Hormone
|
Topics |
- ACTH-Secreting Pituitary Adenoma
(diagnostic imaging, drug therapy, genetics, metabolism)
- Adenoma
(diagnostic imaging, drug therapy, genetics, metabolism)
- Adrenocorticotropic Hormone
(blood)
- Adult
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Female
- Humans
- Ipilimumab
(administration & dosage)
- Liver Neoplasms
(diagnostic imaging, drug therapy, genetics, secondary)
- Magnetic Resonance Imaging
- Mutation
- Nivolumab
(administration & dosage)
|